Treatment outcome of patients with isoniazid mono-resistant tuberculosis

Clinical Microbiology and Infection

Volumn 21, Issue 1, 2015, Pages 59-68

  Chien, J Y ^a,b   Chen, Y T ^c   Wu, S G ^a,d   Lee, J J ^c   Wang, J Y ^a   Yu, C J ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Chest Hospital   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Drug resistant tuberculosis; Isoniazid; Taiwan; Treatment outcome; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; RECURRENT DISEASE; SURVIVAL; TUBERCULOSIS, PULMONARY;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84926391806     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.08.008     Document Type: Article

References (29)

1. World Health Organization Global tuberculosis control: WHO report 2013 2013, WHO, Geneva.
2. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
3. Wright A., Zignol M. Anti-tuberculosis drug resistance in the world: fourth global report: the world health organization/international union against tuberculosis and lung disease (who/union) global project on anti-tuberculosis drug resistance surveillance, 2002-2007 2008, WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance, World Health Organization, Geneva, Switzerland.
4. Mitchison D.A., Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133:423-430.
5. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987, 136:1339-1342.
6. Menzies D., Benedetti A., Paydar A., Royce S., Pai M., Burman W., et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009, 6:e1000150.
7. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
8. Farah M.G., Tverdal A., Steen T.W., Heldal E., Brantsaeter A.B., Bjune G. Treatment outcome of new culture positive pulmonary tuberculosis in norway. BMC Public Health 2005, 5:14.
9. Gegia M., Cohen T., Kalandadze I., Vashakidze L., Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 2012, 16:812-816.
10. Taiwan guidelines for tb diagnosis and treatment 2013, Centers for Disease Control, Taiwan, Taipei, Taiwan. 5th ed. K.T. Luh (Ed.).
11. Murray P.R., Baron E.J. Manual of clinical microbiology 2007, ASM Press, Washington, D.C. 9th ed.
12. Kim S.J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005, 25:564-569.
13. Hsueh P.R., Liu Y.C., So J., Liu C.Y., Yang P.C., Luh K.T. Mycobacterium tuberculosis in Taiwan. JInfect 2006, 52:77-85.
14. Snider G.L., Doctor L., Demas T.A., Shaw A.R. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 1971, 103:625-640.
15. World Health Organization, Stop TB Initiative (World Health Organization) Treatment of tuberculosis: guidelines 2010, World Health Organization, Geneva. 4th ed.
16. Bang D., Andersen P.H., Andersen A.B., Thomsen V.O. Isoniazid-resistant tuberculosis in denmark: Mutations, transmission and treatment outcome. JInfect 2010, 60:452-457.
17. Cattamanchi A., Dantes R.B., Metcalfe J.Z., Jarlsberg L.G., Grinsdale J., Kawamura L.M., et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009, 48:179-185.
18. Jacobson K.R., Theron D., Victor T.C., Streicher E.M., Warren R.M., Murray M.B. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011, 53:369-372.
19. CLSI Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-second edition. CLSI document m24-a2 2011, Clinical and Laboratory Standards Institute, Wayne, PA.
20. Jaramillo E., Stop TB Initiative (World Health Organization), Great Britain.Department for International Development., United States.Agency for International Development Guidelines for the programmatic management of drug-resistant tuberculosis: [emergency update 2008] 2008, Emergency update, World Health Organization, Stop TB Department, Geneva.
21. Babu Swai O., Aluoch J.A., Githui W.A., Thiong'o R., Edwards E.A., Darbyshire J.H., et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 1988, 69:5-14.
22. Fox L., Kramer M.R., Haim I., Priess R., Metvachuk A., Shitrit D. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 2011, 30:863-867.
23. Moulding T.S. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?. Am Rev Respir Dis 1981, 123:262-264.
24. Katiyar S.K., Bihari S., Prakash S., Mamtani M., Kulkarni H. Arandomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008, 12:139-145.
25. Li Z., Kelley C., Collins F., Rouse D., Morris S. Expression of KATG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. JInfect Dis 1998, 177:1030-1035.
26. Wilson T.M., de Lisle G.W., Collins D.M. Effect of inha and KATG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 1995, 15:1009-1015.
27. Burgos M., DeRiemer K., Small P.M., Hopewell P.C., Daley C.L. Effect of drug resistance on the generation of secondary cases of tuberculosis. JInfect Dis 2003, 188:1878-1884.
28. Dorman S.E., Johnson J.L., Goldberg S., Muzanye G., Padayatchi N., Bozeman L., et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
29. Ors F., Deniz O., Bozlar U., Gumus S., Tasar M., Tozkoparan E., et al. High-resolution ct findings in patients with pulmonary tuberculosis: correlation with the degree of smear positivity. JThorac Imaging 2007, 22:154-159.